[The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
OBJECTIVE
To analyze the association of transforming growth factor-beta1(TGF-beta1) gene +869T/C polymorphism and the serum level of TGF-beta1 in patients with early essential hypertension and early renal injury. To study the effect of the gene polymorphism of TGF-beta1 on the individual treatment with valsartan.


METHODS
Eighty patients with early essential hypertension and early renal injury were treated with valsartan, and their polymorphism of TGF-beta1 gene +869T/C was analyzed by sequence specific primers-polymerase chain reaction method. Before valsartan treatment and 8 weeks after the treatment, their urinary microamount albumin (MA) levels were determined by using radioimmunity method, and their serum levels of TGF-beta1 were determined by enzyme-linked immunosorbent assay.


RESULTS
The blood pressure level of patients with TGF-beta 1 gene +869 CC genotype, TT genotype, TC genotype showed no significant difference (P> 0.05) before treatment. The urinary MA level of the three genotypes was CC genotype's > TC genetype's > TT genotype's in sequence, and the urinary MA level of CC genotype was significantly higher than that of TC genotype and of TT genotype (P< 0.01). The serum levels of TGF-beta1 in the three genotypes was CC genotype's > TC genotype's > TT genotype's in sequence (P< 0.01). There was statistically significant positive correlation between the urinary MA level and the serum level of TGF-beta1(P< 0.05). After 8 weeks treatment with valsartan, there was significant decrease of the blood pressure, the urinary MA level, and the serum level of TGF-beta1. However, the blood pressure reduction of the three types had no statistical significant difference in sequence. The absolute value of urinary MA reduction was CC genotype's > TC genotype's > TT genotype's in sequence, the reduction absolute value of urinary MA in CC genotype was higher than that of TC genotype and of TT genotype (P< 0.05), but the reduction percentage of the urinary MA in the three genotypes showed no statistically significant difference (P> 0.05). The reduction of serum levels of TGF-beta1 was CC genotype's > TC genotype's > TT genotype's in sequence, there was significant difference between each other (P< 0.01). However, the reduction percentage of the serum level of TGF-beta 1 in the three types showed no statistically significant difference (P> 0.05).


CONCLUSIONS
(1) The renal injury of CC genotype in patients with early essential hypertension and early renal injury is more serious than that of TC genotype and of TT genotype. (2)The serum level of TGF-beta 1 can accurately indicate the severity of the renal injury and the protective effect on kidney with valsartan in patients with essential hypertension and early renal injury. (3)The treatment effect of valsartan in the patients with different TGF-beta 1 +869T/C genotype has no difference, i.e., besides effectively decreasing the blood pressure and protecting the renal function, valsartan can reduce the serum level of TGF-beta1 without the influence of the gene polymorphism of TGF-beta1.
Department of Cardiology, Qingdao Municipal Hospital, Qingdao, Shandong, 266011 P. R. China.
Chen
C
Zhao
Yun-ying
YY
Wang
Zhi-xiu
ZX
Xiao
Yan-ping
YP
Wang
Qi-yi
QY
Zhang
D000368:Aged; D000419:Albuminuria / Q000652:urine; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics*; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors; D053773:Transforming Growth Factor beta1 / Q000097:blood / Q000235:genetics*; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D000959:Antihypertensive Agents; D013777:Tetrazoles; D053773:Transforming Growth Factor beta1; D000068756:Valsartan; D014633:Valine